Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients

Compass Therapeutics says tovecimig misses overall survival endpoint in biliary tract cancer study, but data shows progression-free survival and response rates. Latest Ratings for CMPX Date Firm Action From To Jan 2022 B. Riley Securities Initiates Coverage On Buy Dec 2021 Raymond James Initiates Coverage On Outperform Dec 2021 SVB Leerink Initiates Coverage On Outperform View More Analyst Ratings for CMPX View the Latest Analyst Ratings Importance Rank: 2 read more

Go to News Site